CL2023001632A1 - Ácidos pirazol piperidin carboxílicos sustituidos - Google Patents
Ácidos pirazol piperidin carboxílicos sustituidosInfo
- Publication number
- CL2023001632A1 CL2023001632A1 CL2023001632A CL2023001632A CL2023001632A1 CL 2023001632 A1 CL2023001632 A1 CL 2023001632A1 CL 2023001632 A CL2023001632 A CL 2023001632A CL 2023001632 A CL2023001632 A CL 2023001632A CL 2023001632 A1 CL2023001632 A1 CL 2023001632A1
- Authority
- CL
- Chile
- Prior art keywords
- diseases
- carboxylic acids
- disease
- preparation
- hypertension
- Prior art date
Links
- NOIXNOMHHWGUTG-UHFFFAOYSA-N 2-[[4-[4-pyridin-4-yl-1-(2,2,2-trifluoroethyl)pyrazol-3-yl]phenoxy]methyl]quinoline Chemical compound C=1C=C(OCC=2N=C3C=CC=CC3=CC=2)C=CC=1C1=NN(CC(F)(F)F)C=C1C1=CC=NC=C1 NOIXNOMHHWGUTG-UHFFFAOYSA-N 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N tetrahydropyridine hydrochloride Natural products C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000008960 Diabetic foot Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 208000019622 heart disease Diseases 0.000 abstract 2
- 208000002815 pulmonary hypertension Diseases 0.000 abstract 2
- 208000007056 sickle cell anemia Diseases 0.000 abstract 2
- 208000004990 Cardiorenal syndrome Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 201000006306 Cor pulmonale Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000034189 Sclerosis Diseases 0.000 abstract 1
- 201000009594 Systemic Scleroderma Diseases 0.000 abstract 1
- 206010042953 Systemic sclerosis Diseases 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 230000003176 fibrotic effect Effects 0.000 abstract 1
- 208000038003 heart failure with preserved ejection fraction Diseases 0.000 abstract 1
- 208000038002 heart failure with reduced ejection fraction Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002685 pulmonary effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a ácidos carboxílicos pirazolo piperidínicos sustituidos, sus sales y a los procesos para su preparación, así como a su uso para la preparación de medicamentos para el tratamiento y/o la profilaxis de enfermedades, en particular enfermedades cardiovasculares y cardíacas, preferentemente insuficiencia cardíaca con fracción de eyección reducida y conservada (ICFEr, ICFEp e ICFErm), hipertensión (HTA), enfermedades arteriales periféricas (EAP, EAPO), enfermedad renal o síndrome cardiorrenal, preferentemente enfermedad renal crónica y diabética (ERC y ERD), enfermedades cardiopulmonares y pulmonares, preferentemente hipertensión pulmonar (HP), y otras enfermedades, preferentemente enfermedades neurodegenerativas y diferentes formas de demencias, enfermedades fibróticas, esclerosis sistémica (ES), enfermedad de célula falciforme (SCD, por sus siglas en inglés), trastornos de cicatrización de heridas tales como úlcera del pie diabético (UPD).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20213020 | 2020-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001632A1 true CL2023001632A1 (es) | 2023-11-10 |
Family
ID=73793025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001632A CL2023001632A1 (es) | 2020-12-10 | 2023-06-06 | Ácidos pirazol piperidin carboxílicos sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US20240051935A1 (es) |
| EP (1) | EP4259617B1 (es) |
| JP (1) | JP2023552583A (es) |
| KR (1) | KR20230118144A (es) |
| CN (1) | CN116710439A (es) |
| AR (1) | AR124297A1 (es) |
| AU (1) | AU2021393988A1 (es) |
| CA (1) | CA3204495A1 (es) |
| CL (1) | CL2023001632A1 (es) |
| CO (1) | CO2023007335A2 (es) |
| CR (1) | CR20230242A (es) |
| DK (1) | DK4259617T3 (es) |
| DO (1) | DOP2023000115A (es) |
| EC (1) | ECSP23040828A (es) |
| ES (1) | ES2997117T3 (es) |
| FI (1) | FI4259617T3 (es) |
| GE (2) | GEP20247649B (es) |
| HR (1) | HRP20241543T1 (es) |
| HU (1) | HUE069255T2 (es) |
| IL (1) | IL303296A (es) |
| LT (1) | LT4259617T (es) |
| MX (1) | MX2023006903A (es) |
| PE (1) | PE20231501A1 (es) |
| PL (1) | PL4259617T3 (es) |
| PT (1) | PT4259617T (es) |
| RS (1) | RS66294B1 (es) |
| SA (1) | SA523441083B1 (es) |
| SI (1) | SI4259617T1 (es) |
| TW (1) | TW202237589A (es) |
| WO (1) | WO2022122914A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4011874A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| EP4011873A1 (en) * | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Substituted pyrazolo piperidine carboxylic acids |
| JP2025518350A (ja) | 2022-06-09 | 2025-06-12 | バイエル・アクチエンゲゼルシヤフト | 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター |
| WO2024163561A1 (en) * | 2023-01-31 | 2024-08-08 | Invivosciences, Inc. | Systems and methods for treating heart failure with preserved ejection fraction |
| WO2025067414A1 (zh) * | 2023-09-27 | 2025-04-03 | 海思科医药集团股份有限公司 | 吡唑羧酸衍生物及其在医药上的应用 |
| TW202535380A (zh) * | 2024-01-30 | 2025-09-16 | 大陸商海思科醫藥集團股份有限公司 | 吡唑羧酸衍生物及其在醫藥上的應用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| EA201070339A1 (ru) * | 2007-09-06 | 2010-10-29 | Мерк Шарп Энд Домэ Корп. | Активаторы растворимой гуанилатциклазы |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| EP2539326B1 (de) | 2010-02-27 | 2017-05-03 | Bayer Intellectual Property GmbH | Bis-arylverknüpfte aryltriazolone und ihre verwendung |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2708539A1 (de) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| US8895583B2 (en) * | 2010-10-28 | 2014-11-25 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| DE102011007272A1 (de) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Verzweigte 3-Phenylpropionsäure-Derivate und ihre Verwendung |
| AU2013312931B2 (en) * | 2012-09-07 | 2017-06-22 | Boehringer Ingelheim International Gmbh | Alkoxy pyrazoles as soluble guanylate cyclase activators |
| WO2015095515A1 (en) * | 2013-12-20 | 2015-06-25 | Novartis Ag | Sgc activators for the treatment of glaucoma |
| JP6623220B2 (ja) | 2014-11-03 | 2019-12-18 | バイエル ファーマ アクチエンゲゼルシャフト | ヒドロキシアルキル置換フェニルトリアゾール誘導体およびその使用 |
| GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
| CN116829545A (zh) * | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
| KR20230118143A (ko) * | 2020-12-10 | 2023-08-10 | 바이엘 악티엔게젤샤프트 | 안과 질환의 치료를 위한 sGC 활성화제의 용도 |
-
2021
- 2021-12-09 WO PCT/EP2021/084987 patent/WO2022122914A1/en not_active Ceased
- 2021-12-09 EP EP21823605.7A patent/EP4259617B1/en active Active
- 2021-12-09 JP JP2023535063A patent/JP2023552583A/ja active Pending
- 2021-12-09 GE GEAP202116287A patent/GEP20247649B/en unknown
- 2021-12-09 PL PL21823605.7T patent/PL4259617T3/pl unknown
- 2021-12-09 PT PT218236057T patent/PT4259617T/pt unknown
- 2021-12-09 GE GEAP202316287A patent/GEAP202316287A/en unknown
- 2021-12-09 LT LTEPPCT/EP2021/084987T patent/LT4259617T/lt unknown
- 2021-12-09 CN CN202180081892.0A patent/CN116710439A/zh active Pending
- 2021-12-09 DK DK21823605.7T patent/DK4259617T3/da active
- 2021-12-09 RS RS20241357A patent/RS66294B1/sr unknown
- 2021-12-09 CA CA3204495A patent/CA3204495A1/en active Pending
- 2021-12-09 FI FIEP21823605.7T patent/FI4259617T3/fi active
- 2021-12-09 SI SI202130234T patent/SI4259617T1/sl unknown
- 2021-12-09 HR HRP20241543TT patent/HRP20241543T1/hr unknown
- 2021-12-09 US US18/256,647 patent/US20240051935A1/en active Pending
- 2021-12-09 HU HUE21823605A patent/HUE069255T2/hu unknown
- 2021-12-09 ES ES21823605T patent/ES2997117T3/es active Active
- 2021-12-09 TW TW110146019A patent/TW202237589A/zh unknown
- 2021-12-09 AR ARP210103422A patent/AR124297A1/es unknown
- 2021-12-09 IL IL303296A patent/IL303296A/en unknown
- 2021-12-09 AU AU2021393988A patent/AU2021393988A1/en active Pending
- 2021-12-09 PE PE2023001808A patent/PE20231501A1/es unknown
- 2021-12-09 KR KR1020237022818A patent/KR20230118144A/ko active Pending
- 2021-12-09 MX MX2023006903A patent/MX2023006903A/es unknown
- 2021-12-09 CR CR20230242A patent/CR20230242A/es unknown
-
2023
- 2023-06-01 EC ECSENADI202340828A patent/ECSP23040828A/es unknown
- 2023-06-02 CO CONC2023/0007335A patent/CO2023007335A2/es unknown
- 2023-06-06 CL CL2023001632A patent/CL2023001632A1/es unknown
- 2023-06-07 SA SA523441083A patent/SA523441083B1/ar unknown
- 2023-06-07 DO DO2023000115A patent/DOP2023000115A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GEAP202316287A (en) | 2023-09-11 |
| AU2021393988A9 (en) | 2024-09-19 |
| ES2997117T3 (en) | 2025-02-14 |
| ECSP23040828A (es) | 2023-07-31 |
| GEP20247649B (en) | 2024-07-25 |
| CA3204495A1 (en) | 2022-06-16 |
| FI4259617T3 (fi) | 2024-11-27 |
| PE20231501A1 (es) | 2023-09-26 |
| TW202237589A (zh) | 2022-10-01 |
| JP2023552583A (ja) | 2023-12-18 |
| MX2023006903A (es) | 2023-06-26 |
| DOP2023000115A (es) | 2023-07-16 |
| HUE069255T2 (hu) | 2025-02-28 |
| LT4259617T (lt) | 2024-12-10 |
| EP4259617B1 (en) | 2024-10-23 |
| AR124297A1 (es) | 2023-03-15 |
| CN116710439A (zh) | 2023-09-05 |
| CO2023007335A2 (es) | 2023-06-09 |
| PL4259617T3 (pl) | 2025-03-17 |
| IL303296A (en) | 2023-07-01 |
| AU2021393988A1 (en) | 2023-06-22 |
| RS66294B1 (sr) | 2025-01-31 |
| DK4259617T3 (da) | 2024-12-09 |
| HRP20241543T1 (hr) | 2025-01-03 |
| WO2022122914A1 (en) | 2022-06-16 |
| EP4259617A1 (en) | 2023-10-18 |
| PT4259617T (pt) | 2024-12-05 |
| SA523441083B1 (ar) | 2025-06-12 |
| US20240051935A1 (en) | 2024-02-15 |
| CR20230242A (es) | 2023-07-19 |
| SI4259617T1 (sl) | 2025-02-28 |
| KR20230118144A (ko) | 2023-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023001632A1 (es) | Ácidos pirazol piperidin carboxílicos sustituidos | |
| ECSP23041151A (es) | Ácidos pirazolo piperidin carboxílicos sustituidos | |
| NZ715983A (en) | Vasoprotective and cardioprotective antidiabetic therapy | |
| JP2015510913A5 (es) | ||
| CU20160013A7 (es) | Polipéptidos cíclicos para el tratamiento de la insuficiencia cardíaca | |
| BR112017010601A2 (pt) | análogos de ureia substituídos em ponte como moduladores de sirtuínas | |
| EP4488371A3 (en) | Compounds and methods for modulating angiotensinogen expression | |
| Yetman | Cardiovascular pharmacotherapy in patients with Marfan syndrome | |
| Raguindin et al. | FP20 The 7 mHz of Love: Assessment of Systolic Function using Bedside Ultrasound of Ten Patients with Chronic Kidney Disease Presenting with Pulmonary Congestion at the Emergency Department of Southern Philippines Medical Center | |
| Tian et al. | Collagen Accumulation Does Not Impair Cardiopulmonary Recovery From Hypoxia, As Assessed Via Admittance Derived Pressure-Volume Loops In Mice | |
| CO2022014517A2 (es) | Derivado de arilo o heteroarilo | |
| Ali | Hypertensive vascular disease | |
| Otaki et al. | Plasma thioredoxin-1 level is associated with renal tubular damage and predicts poor prognosis in patients with chronic heart failure | |
| Schmid et al. | Can goal-directed hemodynamic management improve renal outcome after major non-cardiac surgery?: 4AP3-2 | |
| Creagh-Brown et al. | The cardiovascular management of sepsis | |
| Rajan et al. | 2nd World Heart Congress | |
| Nielsen et al. | ALBUMINURIA: A MEASURE OF GENEALIZED VASCULAR DAMAGE?: PP. 11.431 | |
| Wajima et al. | Does intravenous atropine affect stroke volume variation in man?: 4AP3-3 | |
| Canino et al. | Plasma Concentration Of Gelatinases And Their Inhibitors In Obstructive Sleep Apnea Syndrome | |
| Porteri et al. | EFFECT OF ANTIHYPERTENSIVE TREATMENT WITH FOSINOPRIL ON MECHANICAL PROPERTIES OF SMALL MESENTERIC ARTERIES OF SPONTANEOUSLY HYPERTENSIVE RATS: PP. 11.433 | |
| Foroughi et al. | Cardiovascular Complications and Management After Cardiac Surgery | |
| Withers et al. | THE EFFECTS OF ERYTHROPOIETIN ON THE LOSS OF ANTICONTRACILE FUNCTION OF PERIVASCULAR FAT FOLLOWING HYPOXIA: PP. 11.432 | |
| Garkina et al. | Cardiomyopathy in 38-year-old woman associated with genetic multisystem disorder | |
| Nastroha | Clinical aspects and treatment of ischemic heart disease associated with COPD | |
| UA14788U (en) | Method for treating chronic heart failure in aged patients with systolic dysfunction of left ventricle in setting of ischemic heart disease and hypertonic disease |